Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 3, 2001, Pages 250-254

  Watanabe, M ^a   Tateishi, T ^a   Takezawa, N ^a   Tanaka, M ^a   Kumai, T ^a   Nakaya, S ^a   Kobayashi, S ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Dihydropyrimidine dehydrogenase; Interaction; Pharmacokinetics; PR 350; Radiosensitizer

Indexed keywords

[3 (2 NITROIMIDAZOL 1 YL)METHOXY]BUTANE 1,2,4 TRIOL; DIHYDROPYRIMIDINE DEHYDROGENASE; DORANIDAZOLE; FLUOROURACIL; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; IMIDAZOLE DERIVATIVE; OXIDOREDUCTASE;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; AREA UNDER THE CURVE; BLOOD; CYTOSOL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; ENZYMOLOGY; HALF LIFE TIME; HUMAN; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; CYTOSOL; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUOROURACIL; HALF-LIFE; HUMANS; IMIDAZOLES; LIVER; MALE; OXIDOREDUCTASES; RADIATION-SENSITIZING AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034743359     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000197     Document Type: Article

References (19)

1. SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use
2. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03
3. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice
4. Oxygen distribution in squamous cell carcinoma metastasis and its relationship to outcome of radiation therapy
5. Pharmacokinetics and radiosensitizing effect of PR-350
6. The phenomenon of reoxygenation and its implications for fractionated radiotherapy
7. Protein measurement with the Folin phenol reagent
8. Radiosensitization by a new potent nucleoside analog: 1-(1′,3′,4′-trihydroxy-2′-butoxy)methyl-2- nitroimidazole (RP-343)
9. Studies on the metabolic fate of Brovavir (YN-72) II: Metabolism in rats
10. Phase I clinical study of YN-72 (BV-araU, Brovavir)
11. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs
12. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): Radiosensitization efficiency and toxicity
13. A phase I study of the hypoxic cell radiosensitizer Ro-03-87992
14. Therapeutic attacks of hypoxic cells of solid tumors: Presidential address
15. The clinical testing of Ro 03-8799 pharmacokinetics, toxicology, tissue and tumor concentrations
16. Preliminary examination of the influence of incubation time or cytosolic protein concentration on dihydropyrimidine dehydrogenase activity
17. Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats
18. Radiation therapy oncology group clinical trials with misonidazole